Stifel has upgraded Siegfried Holding AG to a Buy rating from Hold and increased its target price to 90 Swiss francs from 75 francs, citing what the broker describes as an "increasingly de-risked" earnings profile following sharp consensus downgrades over the past 18 months, particularly in the companys Drug Product division.
Consensus cuts create a lower hurdle for growth
Analysts at Stifel noted that their Drug Product forecasts for 2025, 2026 and 2027 were reduced by approximately 7%, 11% and 14%, respectively, which the firm said results in "a much lower hurdle for growth." The brokers own near-term outlook expects first-half 2026 organic sales to fall by 1.3%, while projecting full-year 2026 organic growth of 2.1% as Siegfrieds recently expanded and upgraded facilities come online.
Stifel highlighted several capacity and capability additions that should support the second-half recovery, including the ramp-up of the Minden and DINAMIQS facilities, Barcelona ophthalmics and spray-drying operations, and Hameln fill-finish assets. The upgraded price target of 90 francs implies roughly 17.6% upside from Siegfrieds August 5 closing price of 76.55 francs, according to the report.
Sector backdrop and competitive positioning
The broker pointed to improving CDMO sector fundamentals, noting that returns on invested capital across the contract development and manufacturing organization sector now exceed the cost of capital by the widest margin seen in seven years. Stifel argued that, as a tier-one CDMO with validated Drug Substance and Drug Product platforms and strong regulatory credentials, Siegfried should be among the earlier beneficiaries of recovering demand.
Stifels stated "biggest source of conviction" is the companys exposure to increasingly complex small-molecule therapies. Drawing on its proprietary database of roughly 5,000 approved active pharmaceutical ingredients, the broker said it sees rising demand for advanced formulation technologies such as spray drying and oral solid dosage - areas where Europe and Siegfried are over-indexed.
The firm also pointed to recent contract wins in protein degrader work as an early sign of this thematic shift in demand.
Notable contract and contribution assumptions
Stifel noted management had described one Phase III programme as a potential "game changer," and the broker believes this programme could be Roches Giredestrant. Stifel assigns a peak annual revenue potential of 84.5 million francs to the contracts contribution, a figure it said is more than double the roughly 40 million francs typically generated by a large Siegfried product.
In modeling the revenue impact, Stifel expects the opportunity to add 1.7%, 2.4% and 3.2% to Drug Product growth in 2028, 2029 and 2030, respectively.
Market positioning, short interest and potential catalysts
Short interest in Siegfried remained elevated, at 4.94 million shares or 14.4% of the free float as of July 27, though that level is lower than a peak of 6.26 million shares, or 16% of free float. Stifel reports that days-to-cover have come down to about 45 from roughly 55. The broker suggested that a first-half result that is merely "not-worse-than-feared" or a reiterated guidance could accelerate short covering.
Valuation approach and risks
Stifels valuation is a 50/50 blend of a discounted cash flow model and a multiples analysis. The DCF component uses a 7% weighted average cost of capital and a 1.5% terminal growth rate, while the multiple analysis applies a 12.5 times 2026 estimated EV/EBITDA. The broker flagged several risks to its thesis, including potential FDA warning letters, contamination events in production, overcapacity in the fill-and-finish segment, and higher energy, raw material and labor costs. The report also noted that Siegfried shares are trading at their widest discount to peers in five years.
Summary
Stifel upgraded Siegfried to Buy and raised its price target to 90 francs, arguing that prior consensus cuts have lowered earnings risk for the Drug Product division. The broker points to improving CDMO sector returns, upcoming facility ramps, and Siegfrieds exposure to complex small-molecule formulation demand as key reasons for the upgrade. Short interest, while elevated, has declined from prior peaks and could be unwound should near-term results avoid downside surprises. Stifels valuation blends a DCF and multiples approach and it outlines specific operational and regulatory risks that could derail the thesis.